Al Sandrock has been President and Chief Executive Officer of Voyager Therapeutics, as well as a member of the board of directors, since 2022. He also currently serves as a member of the board of directors for Verge Genomics, Inc.; Transition Bio, Inc.; and Neurimmune, Inc. Sandrock joined Voyager following 23 years at Biogen where he identified and developed novel therapies for a variety of serious diseases. There he served in positions of increasing responsibility, culminating in his service as Executive Vice President, Research and Development. He also served as Chief Medical Officer and held a seat on the Biogen Executive Committee. Over the course of his tenure, he led the discovery, development, and regulatory approval of numerous medicines including ADUHELM™, PLEGRIDY®, SPINRAZA®, TECFIDERA®, and TYSABRI®. Prior to joining Biogen, Sandrock was Assistant Professor of Neurology at Harvard Medical School and was Assistant in Neurology at Massachusetts General Hospital. Sandrock earned a B.A. in human biology from Stanford University, an M.D. from Harvard Medical School, and a Ph.D. in neurobiology from Harvard University. He completed an internship in medicine, a residency and chief residency in neurology, and a clinical fellowship in neuromuscular disease and clinical neurophysiology at Massachusetts General Hospital.